Metabolic Peptides
Retatrutide
Triple incretin agonist RUO peptide with HPLC/MS identity confirmation. Public sequence literature; batch COA on request. Not for human use.
Select Dosage
Retatrutide (39-mer triple GLP-1/GIP/glucagon agonist) is supplied as lyophilized powder in sterile glass vials. Structure is described in public patent and trial literature (e.g. US11542313B2); independent synthesis requires lot-specific HPLC and mass spectrometry — which we provide on request. Strictly for qualified in-vitro and preclinical research under institutional oversight. Not Lilly investigational product; not for injection, weight management, or veterinary use.
Quality & Manufacturing
Third-Party Mass Spectrometry Verified
Every production batch undergoes independent HPLC and mass spectrometry analysis. Certificates of Analysis (COA) are available upon request, documenting peptide identity, purity ≥ 99%, and absence of contaminants.
- HPLC purity ≥ 99.0% on every batch
- MS identity confirmation included
- Endotoxin testing for sterile-grade products
- COA available per lot number